EMA Decision on Durvalumab in NSCLC Is ' Major Cause of Concern ' EMA Decision on Durvalumab in NSCLC Is ' Major Cause of Concern '
Lung cancer experts say the recent decision to restrict the use of durvalumab immunotherapy to patients with high PD-L1 expression is ' a lost therapeutic opportunity. 'Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer